紫杉醇联合洛铂在局部晚期宫颈癌患者术前新辅助化疗中的应用效果

Application effect of paclitaxel combined with lobaplatin in preoperative neoadjuvant chemotherapy for patients with locally advanced cervical cancer

目的探究紫杉醇联合洛铂在局部晚期宫颈癌(LACC)患者术前新辅助化疗中的应用效果。方法选择2017—2018年医院收治的200例LACC患者为研究对象,将其随机分为观察组和对照组,每组100例。观察组在术前新辅助化疗中联合应用紫杉醇和洛铂,对照组在术前新辅助化疗中联合应用紫杉醇和顺铂。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。治疗后,两组CYFRA21-1、SCCAg、DcR3和Survivin水平均降低,且观察组低于对照组(P<0.05)。两组的消化道反应、骨髓抑制发生情况比较,差异无统计学意义(P>0.05)。观察组随访2年总生存率为88.00%,高于对照组的70.00%(P<0.05)。结论在LACC患者术前新辅助化疗中联合应用紫杉醇和洛铂,可提高治疗效果,降低CYFRA21-1、SCCAg、DcR3和Survivin水平,延长患者的生存时间。

Objective To investigate the application effect of paclitaxel combined with lobaplatin in preoperative neoadjuvant chemotherapy for patients with locally advanced cervical cancer(LACC).Methods Two hundred patients with LACC admitted in the hospital from 2017 to 2018 were selected as the research objects and randomly divided into observation group and control group,with 100 cases in each group.The observation group received combination of paclitaxel and lobaplatin in preoperative neoadjuvant chemotherapy,while the control group received combination of paclitaxel and cisplatin in preoperative neoadjuvant chemotherapy.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of CYFRA21-1,SCCAg,DcR3 and Survivin in the two groups decreased,and those of the observation group were lower than the control group(P<0.05).There were no significant differences in gastrointestinal reaction and myelosuppression between the two groups(P>0.05).The 2-year overall survival rate of the observation group was 88.00%,which was higher than 70.00%of the control group(P<0.05).Conclusion The combination of paclitaxel and lobaplatin in preoperative neoadjuvant chemotherapy for patients with LACC can improve the therapeutic effect,reduce the levels of CYFRA21-1,SCCAg,DcR3 and Survivin,and prolong the survival time of patients.